lupus
Exagen Licenses Lupus Nephritis Biomarkers From Johns Hopkins University
The company plans to develop the biomarkers into tests to help with diagnostic and treatment decisions by providing insight into a specific patient's lupus nephritis.
Werfen Nabs 510(k) for Connective Tissue Disease Reagent
The reagent is used to aid in the diagnosis of mixed connective tissue disease, systemic lupus erythematosus, and other connective tissue diseases.
AliveDx Nabs CE Marks for Connective Tissue Disease Tests
AliveDx, formerly Quotient, received the regulatory clearance for a pair of immunoassays designed for use on its fully automated MosaiQ microarray platform.
Ampel BioSolutions Developing Molecular Test to Predict Kidney Damage in Lupus Nephritis Patients
Premium
The test may also be able to identify patients who are most likely to respond to the 45 different drugs for lupus nephritis that are in clinical trials.
Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.
May 11, 2021
Exagen Q1 Revenues Grow 10 Percent
Nov 25, 2019
Nov 12, 2019
Exagen Q3 Revenues Rise 27 Percent
Oct 14, 2019
William Blair, Cowen Initiate Coverage of Exagen
Sep 19, 2019
Exagen Goes Public at $14 per Share
Aug 14, 2019